Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02002598 · ClinicalTrials.gov registry record · Phase 1
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
A Phase 1 study, sponsored by Suzanne Lentzsch, MD.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT02002598: Clinical Trial Phase 1 study, sponsored by Suzanne Lentzsch, MD.
NCT02002598 is a Phase 1 study that was terminated before completion, run by Suzanne Lentzsch, MD. The registered enrollment target is 23 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02002598, a Phase 1 study, was terminated before completion, sponsored by Suzanne Lentzsch, MD.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study is designed to define dose-limiting toxicity and determine preliminary evidence of efficacy of carfilzomib (CFZ) in combination with bendamustine and dexamethasone for patients with newly diagnosed multiple myeloma (MM).
Primary Outcome
MTD defined as the highest dose at which ≤20% of participants experience dose-limiting toxicity (DLT), to define the recommended phase II dose. DLT were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute version 4.0. An AE was considered a DLT if it occurred in cycle 1, was deemed related to study treatment, and was one of peripheral neuropathy ≥grade 2, any non-hematologic AE ≥ grade 3, neutropenia grade 4 lasting ≥7 days or with f
Interventions
- DRUG Dexamethasone
- DRUG Carfilzomib
- DRUG Bendamustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2013-11 |
| Est. Completion | 2023-07-01 |
| Phase | Phase 1 |
Why NCT02002598 stopped before completion
NCT02002598 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT02002598 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02002598 about?
NCT02002598 is a clinical study titled "Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma". This study is designed to define dose-limiting toxicity and determine preliminary evidence of efficacy of carfilzomib (CFZ) in combination with bendamustine and dexamethasone for patients with newly diagnosed multiple myeloma (MM).
What is the current status of trial NCT02002598?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2013-11. Estimated completion is 2023-07-01.
What interventions are being tested in trial NCT02002598?
The interventions under investigation include: Dexamethasone (DRUG), Carfilzomib (DRUG), Bendamustine (DRUG).
Who is sponsoring clinical trial NCT02002598?
This trial is sponsored by Suzanne Lentzsch, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02002598's enrollment target sits among peer trials
23 1596th of 2000 higher than 400 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia